InsidersTradesSigma
Follow the 宣泰医药 stock price and the full insider trade history of the company, a listed issuer based in China. Shares trade on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 宣泰医药 has recorded 2 public disclosures. Market capitalisation: €4bn. The latest transaction was filed on 23 March 2026 (Purchase). Among the most active insiders: 李方立. Every trade is openly available.
2
Insider Decl.
n/a
Thresholds
€6,706
2 ops.
Buy Volume
n/a
n/a
Sell Volume
11Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 16,725 of 29,064 companies
47.7
score / 100
Value29
Quality66
FCF yld1.3%
Earn yld1.1%
EV/EBITDA49.4x
ROE3.3%
Gross mgn39%
Net mgn11%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 23 March 2026
关于 宣泰医药
宣泰医药是一家在上海证券交易所上市的医疗保健和制药公司。它专注于药品的开发和销售。